Everolimus

A derivative of sirolimus and an inhibitor of TOR SERINE-THREONINE KINASES. It is used to prevent GRAFT REJECTION in heart and kidney transplant patients by blocking cell proliferation signals. It is also an ANTINEOPLASTIC AGENT.

Also Known As:

Networked: 4022 relevant articles (580 outcomes, 1388 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Serruys, Patrick W: 94 articles (01/2022 - 05/2005)
2.	Stone, Gregg W: 52 articles (01/2022 - 06/2006)
3.	Onuma, Yoshinobu: 48 articles (01/2022 - 03/2008)
4.	Motzer, Robert J: 47 articles (01/2022 - 12/2006)
5.	Windecker, Stephan: 40 articles (01/2022 - 07/2010)
6.	Escudier, Bernard: 34 articles (01/2022 - 08/2008)
7.	Sabaté, Manel: 34 articles (01/2022 - 12/2011)
8.	Valgimigli, Marco: 33 articles (01/2022 - 12/2011)
9.	Brugaletta, Salvatore: 31 articles (10/2022 - 12/2011)
10.	Choueiri, Toni K: 28 articles (01/2022 - 05/2011)

Related Diseases

1.	Neoplasms (Cancer) 01/15/2014 - "Notably, administration of the mTOR inhibitor everolimus during periods of elevated mTOR improved survival in tumor-bearing mice. " 09/27/2007 - "The probability of survival of everolimus group was significantly greater than the observed in a historical cohort of 14 liver recipients with comparable tumors who did not receive everolimus (100%, 90%, 72% vs. 50%, 29%, 14%) at 6, 12, and 24 months, respectively (HR=4.6, 95% confidence interval: 1.3-16.4; P=0.008). " 12/01/2019 - "Everolimus Is Effective Against Metastatic Solid Pseudopapillary Neoplasm of the Pancreas: A Case Report and Literature Review." 10/01/2017 - "Our three cases of neonatal CR demonstrate that a low-dose everolimus regimen is an effective treatment for tumor regression." 01/01/2015 - "The results demonstrated that everolimus enhanced the therapeutic efficacy of TACE in inhibiting cell proliferation, promoting apoptosis and inhibiting tube formation of endothelial cells by blocking the Akt/mTOR signaling pathway in vitro and inhibiting tumor growth and neoangiogenesis in vivo. "
2.	Breast Neoplasms (Breast Cancer) 02/01/2016 - "Appropriate modification of the everolimus dose and dose delay according to the severity of AEs, with resumption of the optimal dose of everolimus when toxicity has improved, will positively affect patient outcomes in HR+ advanced breast cancer. " 08/19/2020 - "Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models." 01/01/2019 - "Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models." 08/09/2017 - "Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer." 01/01/2013 - "Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer."
3.	Renal Cell Carcinoma (Grawitz Tumor) 10/01/2010 - "In oncology, everolimus has been proven effective for the management of treatment-resistant renal cell carcinoma. " 04/23/2012 - "We report an unexpectedly high efficacy of everolimus as a third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. " 10/01/2013 - "This study evaluates the safety and efficacy of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). " 06/01/2009 - "Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo- controlled phase III trial." 06/01/2009 - "Re: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo- controlled phase III trial."
4.	Neuroendocrine Tumors (Neuroendocrine Tumor) 09/22/2020 - "in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET), the mTOR inhibitor everolimus is associated with significant improvement in progression-free survival (PFS). " 01/01/2016 - "Everolimus Effectively Treats Neuroendocrine Tumors of Gut and Lungs." 01/01/2014 - "The mTOR inhibitor everolimus has shown promising results in some but not all neuroendocrine tumors. " 02/01/2014 - "Medical management of pancreatic neuroendocrine tumors has recently been improved by new molecules of which the mTOR inhibitor everolimus. " 09/01/2012 - "Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors."
5.	Primitive Neuroectodermal Tumors (PNET) 03/01/2013 - "Everolimus significantly improved progression-free survival among patients with pNET in the phase III RADIANT-3 study. " 03/09/2011 - "Since last year, there has been a significant advance in the management of PNET, after reported data confirmed the efficacy of everolimus, an mTOR inhibitor, in patients with advanced disease. " 11/01/2014 - "Although everolimus-based phase II/III trials have improved progression-free survival for pNET, its use has not impacted on prolonging overall survival. " 12/01/2019 - "From this meta-analysis, Lu-DOTATATE showed better therapeutic efficacy and safety profile compared to Everolimus in advanced pNETs." 12/01/2019 - "This systematic review was conducted to compare the therapeutic efficacy and safety profile of Lu-DOTATATE and Everolimus in advanced pNETs. "

Related Drugs and Biologics

1.	TOR Serine-Threonine Kinases
2.	Everolimus
3.	Sirolimus (Rapamycin)
4.	Sunitinib (Sutent)
5.	trans-sodium crocetinate (crocetin)
6.	Hormones (Hormone)
7.	exemestane (Aromasin)
8.	Octreotide (Sandostatin)
9.	Sorafenib (BAY 43-9006)
10.	temsirolimus

Related Therapies and Procedures

1.	Therapeutics
2.	Stents
3.	Drug Therapy (Chemotherapy)
4.	Radiotherapy
5.	Aftercare (After-Treatment)